Authors

Latest:

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Catherine Meador, MD, PhD

Latest:

Insights on Resistance Mechanisms and Sequencing Strategies for DLL3-Targeted and ADC Therapies in ES-SCLC

Panelists discussed advances in overcoming resistance in extensive-stage small cell lung cancer, highlighting promising antibody-drug conjugates and immune-based therapies targeting DLL3 and B7-H3, including bispecific T-cell engagers and CAR T cells, while emphasizing the critical need for biomarkers to guide therapy selection and optimize combinations to improve durability, intracranial activity, and patient outcomes amid the challenges of relapse and immune evasion.

Ellen Ball, ANP-FNP

Latest:

Biomarker Testing Standards-of-Care in Breast and Lung Cancer

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.

Tracy I. George, MD

Latest:

Dr George on the Limitations of Current Diagnostic Tools in Detecting KIT D816V Mutations in ISM

Tracy I. George, MD, discusses and how ultra-sensitive duplex sequencing may address key limitations of current diagnostic tools for indolent systemic mastocytosis.

Anurag Agrawal, MD

Latest:

Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.

Deborah M. Stephens, DO

Latest:

CAR T-Cell Therapies in CLL

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

Pauline Funchain, MD

Latest:

Dr. Funchain on the Rationale for the SWOG S1404 Trial in Melanoma

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

J. Dominic Femino, MD

J. Dominic Femino, MD, is an associate professor of clinical orthopedic surgery at the Keck School of Medicine of USC and the chief of the USC Musculoskeletal Oncology Center.

Latest:

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Conclusions

In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.

Stéphane Champiat MD, PhD

Latest:

Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors

Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.

Kevin Elias, MD

Kevin Elias, MD, is a gynecologic oncologist at Cleveland Clinic.

Latest:

Dr Elias on Outcomes With Niraparib Maintenance Therapy in Ovarian Cancer

Kevin Elias, MD, discusses efficacy data from the PRIMA and NOVA trials evaluating niraparib as maintenance therapy in ovarian cancer.

Piotr Rutkowski, MD

Latest:

Dr Rutkowski on JPB898 With Ipilimumab in Stage III or Metastatic Stage IV Melanoma

Piotr Rutkowski, MD, discusses a trial evaluating the nivolumab biosimilar JPB898 plus ipilimumab in stage III or metastatic stage IV melanoma.

Kara N. Maxwell, MD, PhD

Latest:

Dr Maxwell on Cancer Risk for Males Carrying Germline BRCA Mutations

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

Alvaro Alencar, MD

Alvaro Alencar, MD, a hematologist/oncologist, an associate professor of clinical medicine, and associate chief medical officer in the Division of Hematology at the University of Miami Sylvester Comprehensive Cancer Center.

Latest:

Dr Alencar on the Ongoing Development of NX-5948 in CLL and B-Cell Malignancies

Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.

Logan Roof, MD

Latest:

Dr Roof on Disparities in Lung Cancer Mortality Rates in the United States

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.

Catriona Jamieson, MD, PhD, University of California San Diego

Latest:

Dr. Jamieson on Treatment Considerations in Myelofibrosis

Catriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.

Andrea Visentin, MD

Andrea Visentin, MD, is , an oncologist in the Department of Medicine, Hematology Unit, at the University of Padova in Italy.

Latest:

Dr Visentin on the Relevance of Cost Analysis in Guiding Treatment Sequencing for CLL

Andrea Visentin, MD, discusses the relevance of cost analysis in guiding treatment sequencing for patients with chronic lymphocytic leukemia.

Scott R. Solomon, MD

Latest:

Dr. Solomon on the Rationale For Liso-Cel in Relapsed/Refractory LBCL

Scott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Thomas M. Habermann, MD

Latest:

Dr Habermann on Ongoing Trials in MCL and MZL

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.

Madappa Kundranda, MD, PhD

Latest:

The Future of Pathology With AI: Predicting Prognosis and Personalized Treatment

Núria Agustí, MD

Núria Agustí, MD, is a postdoctoral fellow at MD Anderson Cancer Center in Houston, Texas.

Latest:

Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer

Núria Agustí, MD, discusses patient eligibility in a cohort study assessing adjuvant chemoradiotherapy vs radiotherapy alone in patients with cervical cancer.